SEC Form 4 · accession 0001209191-18-034494
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Morneau
Officer — VP, Finance and Administration
Period of report
May 31, 2018
Accepted (ET)
May 31, 2018 · 7:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF1 | May 31, 2018 | S | 21,551 | $9.25 | D | 94,035 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All 21,551 of the shares were acquired on May 18, 2018 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.